VIKING THERAPEUTICS INC (VKTX)

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such...

3 Things You Need to Know if You Buy Viking Therapeutics Today

Is It Too Late to Buy Viking Therapeutics Stock?

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?

Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.

Notable Tuesday Option Activity: NGNE, VKTX, AVDL

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Viking Therapeutics (VKTX) Shares Cross Below 200 DMA

Is Viking Therapeutics a Buy on the Dip?

Viking stock has slipped more than 20% from its peak.

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

A Fed rate cut and a slew of big earnings reports filled out a busy week.

4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move

All signs are pointing toward its continued success.

Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag

The company's latest presentation supports the idea that its lead program will make billions.

Is Viking Therepautics a Buy Now?

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Why Viking Therapeutics Stock Plummeted After Soaring Today

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data

The biotech reported strong weight loss for higher doses of its experimental obesity pill.

Viking Experimental Obesity Pill Shows Promise in Early Study

Viking Therapeutics Inc. said higher doses of its experimental pill increased patients’ weight loss beyond earlier formulations, strengthening its case to eventually compete with blockbuster shots from Novo Nordisk A/S and Eli Lilly & Co.

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

Viking Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Commit To Purchase Viking Therapeutics At $42, Earn 17.9% Using Options

This High-Flying Stock Just Became a Better Buy

It might not be too late to get in on the party.

Noteworthy Wednesday Option Activity: TTD, VKTX, PTON

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review

The major indexes were mixed for the week.

Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.